Extraordinary radiation super-sensitivity accompanying with sorafenib combination therapy: what lies beneath? - PubMed (original) (raw)

Extraordinary radiation super-sensitivity accompanying with sorafenib combination therapy: what lies beneath?

Jayoung Lee et al. Radiat Oncol J. 2017 Jun.

Abstract

Primary liver tumor, especially hepatocellular carcinoma (HCC), is a common cause of cancer death worldwide. The incidence is generally higher in Asian countries than in western countries. Carcinogenesis of HCC is often associated with hepatitis viral infections. Current standard treatment of HCC is surgical resection or transplantation in patients with early stage disease. However, the patient with advanced stage disease, surgical resection is often limited. Sorafenib or other treatment modalities are not so effective as well. We report a case of unusual radiation super-sensitivity in advanced stage HCC, and review the literature.

Keywords: Hepatocellular carcinoma; Radiotherapy; Sorafenib.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1.

Fig. 1.

Huge right lobe hepatocellular carcinoma with portal vein thrombosis was found on pre-treatment computed tomography image. The tumor was occupying almost entire right lobe of the liver. Initially measured tumor volume was around 3,500 mL.

Fig. 2.

Fig. 2.

Liver tumor had markedly reduced on follow-up abdomen computed tomography image.

Fig. 3.

Fig. 3.

Follow-up chest computed tomography scan revealed the radiation pneumonitis on the right lower lung.

Fig. 4.

Fig. 4.

Patient's re-planning computed tomography (CT) image (A) and the dose volume histogram (DVH) comparison of initial radiotherapy plan (B) with the new adaptive CT simulation image (C) were presented. There were significant right shifts in DVH curves of normal organs due to the liver tumor volume change. GTV, gross tumor volume.

References

    1. Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013;47 Suppl:S2–6. - PMC - PubMed
    1. Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol. 2014;20:4115–27. - PMC - PubMed
    1. Ohri N, Dawson LA, Krishnan S, et al. Radiotherapy for hepatocellular carcinoma: new indications and directions for future study. J Natl Cancer Inst. 2016;108:djw133. - PMC - PubMed
    1. McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011;15:223–43. vii-x. - PMC - PubMed
    1. Brade AM, Ng S, Brierley J, et al. Phase 1 Trial of sorafenib and stereotactic body radiation therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2016;94:580–7. - PubMed

LinkOut - more resources